AtaiBeckley Completes Phase 2b Dosing for VLS-01 in TRD; Eyes MDD Expansion
Event summary
- AtaiBeckley dosed the last patient in its Phase 2b Elumina trial for VLS-01, a DMT-based treatment for treatment-resistant depression (TRD), with topline data expected in Q4 2026.
- The study randomized 156 patients across multiple centers in a double-blind, placebo-controlled design.
- AtaiBeckley plans to advance VLS-01 into Phase 3 for major depressive disorder (MDD) if Phase 2 results are supportive.
- VLS-01 and BPL-003 (in Phase 3 for TRD with Breakthrough Therapy Designation) aim to address a broad spectrum of mood and anxiety disorders.
The big picture
AtaiBeckley's completion of the Phase 2b trial for VLS-01 marks a critical step in its strategy to develop rapid-acting treatments for mental health conditions. The shift toward MDD and potential expansion into generalized anxiety disorder (GAD) reflects broader industry trends toward addressing unmet needs in mood disorders with novel serotonergic mechanisms. Success here could position AtaiBeckley as a key player in the evolving landscape of interventional psychiatry.
What we're watching
- Clinical Efficacy
- Whether VLS-01 demonstrates statistically significant efficacy in TRD to justify Phase 3 advancement into MDD.
- Regulatory Pathway
- The pace at which AtaiBeckley secures regulatory alignment for expanding VLS-01 into broader depressive and anxiety indications.
- Competitive Positioning
- How AtaiBeckley differentiates VLS-01 from BPL-003 in addressing the spectrum of mood disorders, particularly in MDD and GAD.
Related topics